Milestone Pharmaceuticals’ etripamil nasal spray has received China approval for adults with PSVT, triggering a $2.0 million milestone payment. The decision opens an exclusive Greater China commercialization arrangement with Everest Medicines, while Milestone remains eligible for up to $98.0 million in additional milestones and tiered royalties reaching 18% on future sales.

Key Highlights

  • Tiered royalties on future Greater China etripamil sales may reach 18%.
  • Etripamil nasal spray won approval in China for adults with PSVT.
  • The approval triggered a $2.0 million milestone payment.
  • Everest Medicines holds the exclusive Greater China commercialization license, covering Mainland China, Hong Kong, Macau and Taiwan.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) said etripamil nasal spray won approval in China for adults with PSVT, triggering a $2.0 million milestone payment. The decision is the first approval for etripamil outside the United States and gives Everest Medicines the exclusive Greater China commercialization license.

China Approval Opens Everest Commercialization

Everest Medicines will lead commercialization across Greater China, defined in the announcement as Mainland China, Hong Kong, Macau and Taiwan. The approval relied on results from the global key RAPID study and the China-based JX02002 study.